U.S. Markets open in 1 min

QIAGEN (QGEN) Catches Eye: Stock Jumps 9.9%

Zacks Equity Research

QIAGEN N.V. QGEN was a big mover last session, as the company saw its shares rise nearly 10% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 30.9% in the past one-month time frame.

The move came following reports that Thermo Fisher Scientific is considering a takeover of the company.

The company has seen a mixed track record when it comes to estimate revision of one increase and two decreases over the past few weeks, while the Zacks Consensus Estimate for the current quarter hasn’t been in a trend either. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

QIAGEN currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.

QIAGEN N.V. Price

QIAGEN N.V. Price

QIAGEN N.V. price | QIAGEN N.V. Quote

Investors interested in the Medical - Biomedical and Genetics industry may consider Anika Therapeutics Inc. ANIK, which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is QGEN going up? Or down? Predict to see what others think:Up or Down

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.

This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.

See their latest picks free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Anika Therapeutics Inc. (ANIK) : Free Stock Analysis Report
 
QIAGEN N.V. (QGEN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research